VILAZODONE ENHANCES THE ENDURANCE CAPACITY AND IMPROVES THE BIOLOGICAL CHANGES IN TREADMILL TEST IN RATS
The aim of our study was the evaluation of the vilazodone (VLZ) influence on the endurance capacity and biological modifications in rats subjected to forced exercise. Material and methods: For the experiment, 24 white Wistar rats, were randomly assigned into four groups. The substances were administered orally, in a single daily dose, for 14 consecutive days: Group 1 (Negative control): distilled water 0.3 mL/100g body without effort; Group 2 (Positive control): distilled water 0.3 mL/100g body subjected to effort; Group 3 (Mg): 200 mg/kg body magnesium chloride; Group 4 (VLZ): 20 mg/kg body vilazodone. The rats motor behavior and the endurance capacity were evaluated using the treadmill test, and some blood parameters, estimating the stress influence were assessed: The investigation protocol was approved and implemented according to recommendations of the “Grigore T. Popa” University of Medicine and Pharmacy Iasi Committee for Research and Ethical Issues. Results: The administration of VLZ resulted in a prolongation in distance traveled, an increase in the number of touches the opposite end of belt and a diminution in the number of delivered shocks. Moreover, it decreased the blood levels of glucose and cortisol, and increased the serum values of brain derived neurotrophic factor. The use of VLZ was accompanied by an intensification of anti-oxidant enzymes activity, respectively a decrease of the oxidative stress marker level in blood. Its effects were less intense, when compared to Mg. Conclusions: The treatment with VLZ improved the physical performances and the endurance capacity in this experimentally-induced stress model in rats. The use of this antidepressant drug recovered the biochemical changes and produced antioxidant effects in animals subjected to forced exercise in treadmill test.
2. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2007; 173: 28-40.
3. Nagy C, Vaillancourt K, Turecki G. A role for activity-dependent epigenetics in the development and treatment of major depressive disorder. Genes Brain Behav 2018; 17: e12447: 1-9.
4. Uchida S, Yamagata H, Seki T et al. Epigenetic mechanisms of major depression: Targeting neuronal plasticity. Psychiat Clin Neurosci 2018; 72: 212-227.
5. Dirven BCJ, Homberg JR, Kozicz T, et al. Epigenetic programming of the neuroendocrine stress response by adult life stress. J Mol Endocrinol 2017; 59: R11-R31.
6. Branchi I. The double-edged sword of neural plasticity: increasing serotonin levels leads to both greater vulnerability to depression and improved capacity to recover. Psychoneuroendocrinol 2011; 37: 339-351.
7. Shi L, Wang J, Xu S, Lu Y. Efficacy and tolerability of vilazodone for major depressive disorder: evidence from phase III/IV randomized controlled trials. Drug Design Develop Ther 2016; 10: 3899-3907.
8. Sahli Z, Banerjee P, Tarazi F. The preclinical and clinical effects of vilazodone for the treatment of major depressive disorder. Expert Opin Drug Discov 2016; 11(5): 515-523.
10. Papadakis MA, McPhee SJ. Current Medical Diagnosis & Treatment 2015, 54th Edition, McGraw Hill Education, 2015, USA.
11. Dale E, Bang-Andersen B, Sanchez C. Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs. Biochem Pharmacol 2015; 95: 81-97.
12. Zhang XF, Wu L, Wan DJ, et al. Evaluation of the efficacy and safety of vilazodone for treating major depressive disorder. Neuropsychiatr Dis Treat 2015; 11: 1957-1965.
13. Wang XQ, Wang GW. Effects of treadmill exercise intensity on spatial working memory and long-term memory in rats. Life Sci 2016; 149: 96-103.
14. Parasuraman S, Raveendran R, Kesavan R. Blood sample collection in small laboratory animals. J Pharmacol Pharmacother 2010; 1(2): 87-93.
15. Elfving B, Plougmann PH, Wegener G. Detection of brain-derived neurotrophic factor (BDNF) in rat blood and brain preparations using ELISA: pitfalls and solutions. J Neurosci Methods 2010; 187(1): 73-77.
16. Directive 2010/73/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes. http://eur-lex. europa. eu/ legal-content/ EN/TXT/ ?uri=CELEX:32010L0073.
17. McEwen BS. Protective and damaging effects of stress mediators: central role of the brain. Dialogues Clin Neurosci 2007; 8: 377-381.
18. Nakagawa Y, To M, Saruta J, et al. Effect of social isolation stress on saliva BDNF in rat. J Oral Sci 2019; 61(4): 516-520.
19. Aydemir O, Deveci A, Taneli F. The effect of chronic antidepressant treatment on serum brain-derived neuro-trophic factor levels in depressed patients: a preliminary study. Prog Neuropsycho-pharmacol Biol Psychiatry 2005; 29: 261-265.
20. JiaWen W, Hong S, ShengXiang X, et al. Depression- and anxiety-like behavior is related to BDNF/TrkB signaling in a mouse model of psoriasis. Clin Exp Dermatol 2018; 43(3): 254-271.
21. Zaletel I, Filipović D, Puškaš N. Hippocampal BDNF in physiological conditions and social isolation. Rev Neurosci 2017; 28(7): 775-792.
22. Hing B, Sathyaputri L, Potash JB. A comprehensive review of genetic and epigenetic mechanisms that regulate BDNF expression and function with relevance to major depressive disorder. Am J Med Genet B Neuropsychiatr Genet 2018; 177(2): 143-177.
23. Deyama D, Bang E, Kato T, et al. Neurotrophic and antidepressant actions of brain-derived neu-rotrophic factor require vascular endothelial growth factor. Biol Psychiatry 2019; 87(2): 143-152.
24. Bazzari AH, Bazzari FH. BDNF therapeutic mechanisms in neuropsychiatric disorders. Int J Mol Sci 2022; 23: 8417.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Once an article is accepted for publication, MSJ requests a transfer of copyrights for published articles.
COPYRIGHT TRANSFER FORM FOR
REVISTA MEDICO-CHIRURGICALĂ A SOCIETĂȚII DE MEDICI ȘI NATURALIȘTI DIN IAȘI /
THE MEDICAL-SURGICAL JOURNAL OF THE SOCIETY OF PHYSICIANS AND NATURALISTS FROM IASI
We, the undersigned authors of the manuscript entitled
warrant that this manuscript, which is submitted for publication in the REVISTA MEDICO-CHIRURGICALĂ, has not been published and it is not under consideration for publication in another journal.
- we give the consent for publication in the REVISTA MEDICO-CHIRURGICALĂ, in printed and electronic format and we transfer unconditioned and complete the copyright of this manuscript to the REVISTA MEDICO-CHIRURGICALĂ, in the event of its acceptance.
- the manuscript does not break the intellectual property rights of any other person.
- we have read the submitted version of the manuscript and we are fully responsible for the content.
Names and signatures of authors / copyright owners (the following sequence is the authorship of the article):
N.B. All the authors must sign this form